《大行报告》瑞银首予诺辉健康(06606.HK)「买入」评级 目标价80.16元
瑞银发表研究报告,首予诺辉健康(06606.HK)「买入」评级,目标价80.16元。报告称,公司於2015年成立,属早期癌症筛查的内地先驱,亦迈向行业领导地位。其产品常卫清(ColoClear)及噗噗管(Pupu Tube)联合用於直肠癌筛查,瞄准面对不同风险的群体,另其产品UU Tube和CerviClear则分别用於筛查胃癌及子宫颈癌。
报告称,其核心产品常卫清是内地唯一获许可直肠癌筛查产品,於去年11月推出。该行料常卫清2021至2024年各年销售分别9,600万、2.02亿、4.03亿及8.05亿元人民币。瑞银形容,常卫清商业化属未来数年主要关注点。
瑞银解释,常卫清正面对庞大但未被重视的市场,因内地大部分民众未有定期照大肠镜习惯。今年3月,诺辉健康与英国阿斯利康订三年协议,在公立医院、药房及互联网渠道联合推广常卫清。该行预期公司将为直接面向消费者(DTC)渠道制订更具体市场策略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.